Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Venture Global Chief Financial Officer Jonathan W. Thayer completed $50.5 million in Class A share sales and exercised more than 2.6 million options in mid-March 2026, while also receiving a new option grant. The transactions occurred as the stock trades well above the company’s assessed Fair Value by InvestingPro and after Venture Global reported …
Zscaler, Inc. Chief Product Officer Adam Geller sold 3,579 shares of company stock across two transactions on March 17 and 18, 2026, raising $554,031. One sale covered tax withholding from vested restricted stock units; the other was executed under a Rule 10b5-1 plan adopted in March 2025. The transactions leave Geller with 46,949 shares. The sales…
Keith D. Larson, General Counsel and Secretary of Venture Global, completed significant Class A Common Stock sales totaling roughly $76.8 million on March 18 and 19, 2026, while also acquiring shares by exercising options and receiving a new option grant. The insider moves coincide with a sharp year-to-date share price rise and come after a quarter…
Noble Corp plc Executive Vice President and CFO Richard B. Barker sold 150,000 A Ordinary Shares on March 18, 2026, generating roughly $6.9 million in proceeds through two transactions executed under a Rule 10b5-1 plan. The sale occurred while the stock sits close to its 52-week peak and after the company posted mixed fourth-quarter 2025 results an…
Noble Corp PLC President and CEO Robert W. Eifler sold 100,000 company shares on March 18, 2026, for $4.6 million in two tranches executed under a Rule 10b5-1 plan. The company posted mixed fourth-quarter 2025 results, with an EPS shortfall against expectations but revenue above forecasts. External analysis flags the stock as overvalued relative to…
The U.S. Securities and Exchange Commission has begun recruiting for a dedicated Sarbanes-Oxley enforcement unit while an independent accounting oversight body is reducing staff, according to job postings and a person familiar with the matter. The actions signal a potential consolidation of certain auditing oversight responsibilities within the SEC…
Deborah Stein, a director at RB Global INC (NYSE: RBA), bought 400 shares on March 18, 2026, for $98.74 each, a total outlay of $39,496. The transaction raised her direct holdings to 1,400 shares. The purchase price exceeded the prevailing share price of $95.84, while InvestingPro’s Fair Value assessment indicates the stock remains undervalued. Sep…
Stoke Therapeutics Chief Financial Officer Thomas Leggett sold 5,378 shares of company stock on March 17 and 18, 2026, in a series of transactions that generated $147,144. The disposition was reported as an issuer-mandated sale to satisfy tax withholding tied to vested restricted stock units. The trades come amid mixed signals for the company: stro…
Paul A. Maleh, president and CEO of CRA International, sold 7,182 shares on March 17, 2026, for a total of $1.16 million under a Rule 10b5-1 trading plan. The company reported record revenue for the fourth quarter and full year of 2025, topping revenue estimates but narrowly missing EPS forecasts. CRAI shares traded near their 52-week low amid thos…
Jason Hoitt, chief patient officer at Stoke Therapeutics (NASDAQ: STOK), sold 3,712 shares of common stock on March 17-18, 2026 to satisfy tax withholding obligations tied to restricted stock unit vesting. The transactions totaled $119,310 and leave Hoitt with 10,276 shares. The company also disclosed executive compensation details and updated clin…
Federal prosecutors in Miami have issued a subpoena to former FBI Director James Comey as part of a Justice Department investigation into government officials who previously investigated or prosecuted Donald Trump. The probe, which has produced more than 130 subpoenas since last year, targets senior officials from the Obama and Biden administration…
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, sold 8,995 shares of company stock across transactions on March 17 and 18, 2026, generating approximately $285,900. The sales were disclosed as mandated transactions to satisfy tax withholding tied to restricted stock unit vesting and settlement. Separately, Stoke's boar…
Anduril Industries will begin assembling its FURY high-speed, 'loyal wingman' combat drones in the coming days at the new Arsenal-1 manufacturing campus in Ohio. The $1 billion facility, located about 20 miles south of Columbus, is slated to employ more than 4,000 people over the next decade, with an initial workforce of roughly 250 by year-end. An…
ServiceTitan Chief Executive Officer Ara Mahdessian sold $159,874 of Class A Common Stock in multiple transactions on March 18, 2026, and converted 2,289 Class B shares into Class A stock. The stock has faced notable declines recently even as the company posted better-than-expected fourth-quarter results and analysts adjusted earnings and price tar…
Medpace Holdings President Jesse J. Geiger sold 31,707 shares on March 17, 2026, generating roughly $14.44 million. The transaction accompanied an exercise of options for the same number of shares at $138.87, which vested on February 15, 2026. Recent analyst activity has reflected evolving sentiment on Medpace's valuation and market position.
Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 shares on March 17, 2026, and exercised options to acquire 5,000 additional shares the same day. The stock has risen since the sale and Enliven reported positive initial Phase 1b results for ELVN-001 in chronic myeloid leukemia, while also appointing Scott Garland to its boa…
Andrew H. Rubenstein, CEO and President of Accel Entertainment, sold 3,938 shares of Class A-1 Common Stock on March 17, 2026, for roughly $44,223. The transaction occurred as the company reported robust fourth-quarter 2025 results and as an analyst firm raised its price target while maintaining a Market Outperform rating. Valuation metrics cited i…
Alaleh Nouri, Executive Vice President and CLO at PROCEPT BioRobotics Corp, sold 5,363 shares of company stock on March 19, 2026, for approximately $139,230 under a Rule 10b5-1 trading plan. The transaction occurred while shares trade at $25.68, down 56% over the past year. The company recently launched its HYDROS Robotic System in the U.K., added …
ServiceTitan, Inc. (TTAN) reported that Director and President Vahe Kuzoyan sold 3,221 shares of Class A common stock on March 18, 2026, for a total of $224,984. The trades were executed at an average price of $69.86, with individual transactions ranging from $68.33 to $74.16. On the same day Kuzoyan converted an equal number of Class B shares into…
Leonard M. Tannenbaum, a director and ten percent owner of Advanced Flower Capital Inc. (NASDAQ:AFCG), bought 151,200 shares of the company's common stock in two transactions on March 18 and March 19, 2026, at $2.59 per share for a total of $391608. The purchases leave him with more than 6.19 million shares directly and additional indirect holdings…
Richard Page Howard, a trustee of North European Oil Royalty Trust (NRT), sold 25,000 units of the trust on March 17, 2026 in two separate trades that together generated $215,601. After the sales, Howard retains direct ownership of 250,000 units. The trust currently yields 9.02% and, according to analysis cited, remains undervalued relative to its …
ServiceTitan Chief Financial Officer Sherry David sold 17,777.5 shares of Class A common stock on March 18, 2026, generating $1.24 million at an average trade price of $69.86 per share. The disposal, executed across several price tranches, was made to meet tax obligations arising from restricted stock unit vesting. The company recently reported bet…
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,261 shares on March 17, 2026 under a Rule 10b5-1 plan, realizing $74,416. The company recently reported fourth-quarter 2025 results that missed consensus on both EPS and revenue and is contending with an activist campaign from a holder of roughly 7.3% of shares.
Director Mark Froimson sold 500 shares of Pacira BioSciences Inc. (NASDAQ: PCRX) on March 17, 2026, in a Form 4 filing. The trade, at $21.81 per share for $10,905, leaves Froimson with 20,136 shares. Pacira reported fourth-quarter 2025 results that missed EPS and revenue expectations, and activist investor DOMA Perpetual Capital Management LLC has …
Core Natural Resources Executive Chair and CEO James A. Brock sold 40,760 shares on March 18, 2026, receiving $4,122,874 at a weighted average price of $101.15. The sale occurred as the company's stock trades near a 52-week high, and follows a temporary shutdown at the Mountaineer II mine after an MSHA imminent danger order tied to elevated methane…
